284 related articles for article (PubMed ID: 32409608)
1. Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase.
Drosu NC; Edelman ER; Housman DE
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12368-12374. PubMed ID: 32409608
[TBL] [Abstract][Full Text] [Related]
2. Efficient Translation of Epstein-Barr Virus (EBV) DNA Polymerase Contributes to the Enhanced Lytic Replication Phenotype of M81 EBV.
Church TM; Verma D; Thompson J; Swaminathan S
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263273
[TBL] [Abstract][Full Text] [Related]
3. Niclosamide inhibits lytic replication of Epstein-Barr virus by disrupting mTOR activation.
Huang L; Yang M; Yuan Y; Li X; Kuang E
Antiviral Res; 2017 Feb; 138():68-78. PubMed ID: 27939840
[TBL] [Abstract][Full Text] [Related]
4. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
5. Chidamide Induces Epstein-Barr Virus (EBV) Lytic Infection and Acts Synergistically with Tenofovir to Eliminate EBV-Positive Burkitt Lymphoma.
Xu L; Zhang M; Tu D; Lu Z; Lu T; Ma D; Zhou Y; Zhang S; Ma Y; Yan D; Wang X; Sang W
J Pharmacol Exp Ther; 2023 Dec; 387(3):288-298. PubMed ID: 37875309
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
Callebaut C; Stepan G; Tian Y; Miller MD
Antimicrob Agents Chemother; 2015 Oct; 59(10):5909-16. PubMed ID: 26149992
[TBL] [Abstract][Full Text] [Related]
7. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.
Meng Q; Hagemeier SR; Fingeroth JD; Gershburg E; Pagano JS; Kenney SC
J Virol; 2010 May; 84(9):4534-42. PubMed ID: 20181711
[TBL] [Abstract][Full Text] [Related]
8. Mutant Cellular AP-1 Proteins Promote Expression of a Subset of Epstein-Barr Virus Late Genes in the Absence of Lytic Viral DNA Replication.
Lyons DE; Yu KP; Vander Heiden JA; Heston L; Dittmer DP; El-Guindy A; Miller G
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021895
[TBL] [Abstract][Full Text] [Related]
9. Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase.
Whitehurst CB; Sanders MK; Law M; Wang FZ; Xiong J; Dittmer DP; Pagano JS
J Virol; 2013 May; 87(9):5311-5. PubMed ID: 23449792
[TBL] [Abstract][Full Text] [Related]
10. Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation.
Thomé MP; Borde C; Larsen AK; Henriques JAP; Lenz G; Escargueil AE; Maréchal V
Antiviral Res; 2019 Dec; 172():104615. PubMed ID: 31580916
[TBL] [Abstract][Full Text] [Related]
11. Latent and lytic Epstein-Barr virus replication strategies.
Tsurumi T; Fujita M; Kudoh A
Rev Med Virol; 2005; 15(1):3-15. PubMed ID: 15386591
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin Modification of the Epstein-Barr Virus Immediate Early Transactivator Zta.
Zhao M; Nanbo A; Becnel D; Qin Z; Morris GF; Li L; Lin Z
J Virol; 2020 Oct; 94(22):. PubMed ID: 32847852
[TBL] [Abstract][Full Text] [Related]
13. Uracil DNA glycosylase BKRF3 contributes to Epstein-Barr virus DNA replication through physical interactions with proteins in viral DNA replication complex.
Su MT; Liu IH; Wu CW; Chang SM; Tsai CH; Yang PW; Chuang YC; Lee CP; Chen MR
J Virol; 2014 Aug; 88(16):8883-99. PubMed ID: 24872582
[TBL] [Abstract][Full Text] [Related]
14. DNA Damage Signaling Is Induced in the Absence of Epstein-Barr Virus (EBV) Lytic DNA Replication and in Response to Expression of ZEBRA.
Wang'ondu R; Teal S; Park R; Heston L; Delecluse H; Miller G
PLoS One; 2015; 10(5):e0126088. PubMed ID: 25950714
[TBL] [Abstract][Full Text] [Related]
15. The Translesion Polymerase Pol η Is Required for Efficient Epstein-Barr Virus Infectivity and Is Regulated by the Viral Deubiquitinating Enzyme BPLF1.
Dyson OF; Pagano JS; Whitehurst CB
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724765
[TBL] [Abstract][Full Text] [Related]
16. (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves ERK1/2 and PI3-K/Akt signaling in EBV-positive cells.
Liu S; Li H; Chen L; Yang L; Li L; Tao Y; Li W; Li Z; Liu H; Tang M; Bode AM; Dong Z; Cao Y
Carcinogenesis; 2013 Mar; 34(3):627-37. PubMed ID: 23180656
[TBL] [Abstract][Full Text] [Related]
17. Prazoles Targeting Tsg101 Inhibit Release of Epstein-Barr Virus following Reactivation from Latency.
Mannemuddhu SS; Xu H; Bleck CKE; Tjandra N; Carter C; Bhaduri-McIntosh S
J Virol; 2021 Jun; 95(13):e0246620. PubMed ID: 33853959
[TBL] [Abstract][Full Text] [Related]
18. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
20. BZLF1 controlled by family repeat domain induces lytic cytotoxicity in Epstein-Barr virus-positive tumor cells.
Wang H; Zhao Y; Zeng L; Tang M; El-Deeb A; Li JJ; Cao Y
Anticancer Res; 2004; 24(1):67-74. PubMed ID: 15015577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
